Idiopathic pulmonary fibrosis: state of the art for 2023

AJ Podolanczuk, CC Thomson… - European …, 2023 - Eur Respiratory Soc
Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease characterised by
worsening respiratory symptoms and physiological impairment. Increasing awareness of the …

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary …

M Humbert, G Kovacs, MM Hoeper… - European heart …, 2022 - academic.oup.com
Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and may be associated with a variety of cardiovascular and respiratory …

A global view of pulmonary hypertension

MM Hoeper, M Humbert, R Souza, M Idrees… - The Lancet …, 2016 - thelancet.com
Pulmonary hypertension is a substantial global health issue. All age groups are affected with
rapidly growing importance in elderly people, particularly in countries with ageing …

Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management

F Luppi, M Kalluri, P Faverio, M Kreuter, G Ferrara - Respiratory Research, 2021 - Springer
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive disorder with an estimated
median survival time of 3–5 years after diagnosis. This condition occurs primarily in elderly …

Pulmonary hypertension associated with lung diseases

OA Shlobin, Y Adir, JA Barbera… - European …, 2024 - publications.ersnet.org
Pulmonary hypertension (PH) associated with chronic lung disease (CLD) is both common
and underrecognised. The presence of PH in the setting of lung disease has been …

[HTML][HTML] Physiology of the lung in idiopathic pulmonary fibrosis

L Plantier, A Cazes, AT Dinh-Xuan… - European …, 2018 - Eur Respiratory Soc
The clinical expression of idiopathic pulmonary fibrosis (IPF) is directly related to multiple
alterations in lung function. These alterations derive from a complex disease process …

Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide

D Krewski, RA Yokel, E Nieboer… - Journal of Toxicology …, 2007 - Taylor & Francis
Full article: Human Health Risk Assessment for Aluminium, Aluminium Oxide, and Aluminium
Hydroxide Skip to Main Content Taylor and Francis Online homepage Taylor and Francis …

Pulmonary hypertension associated with lung disease: new insights into pathomechanisms, diagnosis, and management

KM Olsson, TJ Corte, JC Kamp, D Montani… - The Lancet …, 2023 - thelancet.com
Patients with chronic lung diseases, particularly interstitial lung disease and chronic
obstructive pulmonary disease, frequently develop pulmonary hypertension, which results in …

Validation of proposed criteria for progressive pulmonary fibrosis

JV Pugashetti, A Adegunsoye, Z Wu… - American journal of …, 2023 - atsjournals.org
Rationale: Criteria for progressive pulmonary fibrosis (PPF) have been proposed, but their
prognostic value beyond categorical decline in FVC remains unclear. Objectives: To …

Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities

CS King, SD Nathan - The Lancet Respiratory Medicine, 2017 - thelancet.com
Despite the development of pharmacological therapies that are effective in slowing the
progression of idiopathic pulmonary fibrosis (IPF), it remains a debilitating and lethal …